Home › Funds › ARCH Venture Management, LLC › VIR
ARCH Venture Management, LLC position in VIR
VIR BIOTECHNOLOGY INC · Health Care
ARCH Venture Management, LLC reported holding 12,694,163 shares of VIR (VIR BIOTECHNOLOGY INC) in its Q2 2026 13F filing — a position valued at US$129.4M, representing 11.76% of its reported portfolio and ranking #6 among its reported holdings. ARCH Venture Management, LLC has disclosed VIR holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ARCH Venture Management, LLC's VIR position evolved
ARCH Venture Management, LLC first disclosed a stake in VIR in Q2 2025 at 12,916,663 shares (US$65.1M). The position peaked in Q2 2026 at 12,694,163 shares, worth US$129.4M. Across 5 filings, ARCH Venture Management, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 12,694,163 shares valued at US$129.4M — a reduction of -222,500 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 12.92M | $65.10M | New |
| Q3 2025 | 12.92M | $73.75M | Hold |
| Q4 2025 | 12.92M | $77.89M | Hold |
| Q1 2026 | 12.92M | $115.73M | Hold |
| Q2 2026 | 12.69M | $129.35M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VIR and 13F data
VIR (VIR BIOTECHNOLOGY INC) is a Health Care company. 49 other funds we track also report a position in VIR — the largest reported positions include SB INVESTMENT ADVISERS (UK) LTD (US$111.6M), GSK plc (US$87.1M), ADAR1 Capital Management, LLC (US$25.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VIR
- SB INVESTMENT ADVISERS (UK) LTD 10.95M sh · $111.56M · Q2 2026
- GSK plc 8.55M sh · $87.13M · Q2 2026
- ADAR1 Capital Management, LLC 2.46M sh · $25.03M · Q2 2026
- Boxer Capital Management, LLC 1.87M sh · $19.01M · Q2 2026
- GordonMD Global Investments LP 1.35M sh · $13.79M · Q2 2026
- Sio Capital Management, LLC 1.08M sh · $10.96M · Q2 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 853.68K sh · $8.70M · Q2 2026
- Saturn V Capital Management LP 770.64K sh · $7.85M · Q2 2026
- Jones Hill Capital LP 659.21K sh · $6.72M · Q2 2026
- Avidity Partners Management LP 519.30K sh · $5.29M · Q2 2026
- Alta Partners Management Company, L.P. 509.92K sh · $5.20M · Q2 2026
More on ARCH Venture Management, LLC
FAQ
How long has ARCH Venture Management, LLC held VIR?
ARCH Venture Management, LLC has disclosed VIR holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
What is ARCH Venture Management, LLC's current position in VIR?
As of Q2 2026, ARCH Venture Management, LLC holds 12.69M shares of VIR (VIR BIOTECHNOLOGY INC), valued at $129.35M, representing 11.76% of its reported portfolio and ranking #6.
Has ARCH Venture Management, LLC been buying or selling VIR?
In the latest 13F filing (Q2 2026), ARCH Venture Management, LLC reduced its position in VIR. The position peaked in Q2 2026 at 12.69M shares.
Which other funds hold VIR?
Other major institutional holders of VIR include SB INVESTMENT ADVISERS (UK) LTD, GSK plc, ADAR1 Capital Management, LLC, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.